These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 28625654)

  • 1. LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
    Imperatori A; Sahnane N; Rotolo N; Franzi F; Nardecchia E; Libera L; Romualdi C; Cattoni M; Sessa F; Dominioni L; Furlan D
    Lung Cancer; 2017 Jun; 108():83-89. PubMed ID: 28625654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
    Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
    Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.
    Camps C; Jantus-Lewintre E; Cabrera A; Blasco A; Sanmartín E; Gallach S; Caballero C; del Pozo N; Rosell R; Guijarro R; Sirera R
    Lung Cancer; 2011 Jun; 72(3):365-9. PubMed ID: 21074889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
    Sawa K; Koh Y; Kawaguchi T; Kambayashi S; Asai K; Mitsuoka S; Kimura T; Yoshimura N; Yoshimoto N; Kubo A; Saka H; Matsumura A; Wanibuchi H; Yamamoto N; Nishiyama N; Hirata K
    Lung Cancer; 2017 Oct; 112():96-101. PubMed ID: 29191607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of promoter CpG island hypermethylation and repetitive DNA hypomethylation in stage I lung adenocarcinoma.
    Rhee YY; Lee TH; Song YS; Wen X; Kim H; Jheon S; Lee CT; Kim J; Cho NY; Chung JH; Kang GH
    Virchows Arch; 2015 Jun; 466(6):675-83. PubMed ID: 25772390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential
    Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component.
    Pan Y; Wang R; Ye T; Li C; Hu H; Yu Y; Zhang Y; Wang L; Luo X; Li H; Li Y; Shen L; Sun Y; Chen H
    Chest; 2014 Mar; 145(3):473-479. PubMed ID: 24158231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
    Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.
    Bar J; Damianovich M; Hout Siloni G; Dar E; Cohen Y; Perelman M; Ben Nun A; Simansky D; Yellin A; Urban D; Onn A
    Clin Lung Cancer; 2014 Mar; 15(2):159-65. PubMed ID: 24370118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
    Macerelli M; Caramella C; Faivre L; Besse B; Planchard D; Polo V; Ngo Camus M; Celebic A; Koubi-Pick V; Lacroix L; Pignon JP; Soria JC
    Lung Cancer; 2014 Mar; 83(3):383-8. PubMed ID: 24439569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a specific phenotype associated with the different subtypes of KRAS mutations in patients with advanced non-small-cell lung cancers?
    Dumenil C; Vieira T; Rouleau E; Antoine M; Duruisseaux M; Poulot V; Lacave R; Cadranel J; Massiani MA; Wislez M
    Lung Cancer; 2015 Dec; 90(3):561-7. PubMed ID: 26520186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.
    Boros A; Lacroix L; Lacas B; Adam J; Pignon JP; Caramella C; Planchard D; de Montpreville V; Deutsch E; Levy A; Besse B; Le Pechoux C
    Oncotarget; 2017 Apr; 8(15):25189-25199. PubMed ID: 28445990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients.
    Maeng CH; Lee HY; Kim YW; Choi MK; Hong JY; Jung HA; Lee KS; Kim H; Kwon OJ; Sun JM; Ahn JS; Park K; Um SW; Ahn MJ
    Anticancer Res; 2013 Nov; 33(11):5127-33. PubMed ID: 24222160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hot spot mutations in Finnish non-small cell lung cancers.
    Mäki-Nevala S; Sarhadi VK; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuuttila A; Knuutila S
    Lung Cancer; 2016 Sep; 99():102-10. PubMed ID: 27565922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.
    Ooki A; Maleki Z; Tsay JJ; Goparaju C; Brait M; Turaga N; Nam HS; Rom WN; Pass HI; Sidransky D; Guerrero-Preston R; Hoque MO
    Clin Cancer Res; 2017 Nov; 23(22):7141-7152. PubMed ID: 28855354
    [No Abstract]   [Full Text] [Related]  

  • 20. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
    Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
    J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.